MedTrace Logo

A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

NCT06015841 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-11-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease.

Conditions

  • Parkinson Disease
  • Parkinson Disease 6, Early-Onset

Interventions

BIOLOGICAL

Placebo

The placebo is a solution matching the study treatment formulation.

BIOLOGICAL

ACI-7104.056 at Dose A

The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.

BIOLOGICAL

ACI-7104.056 at Dose B (optional)

The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.

BIOLOGICAL

ACI-7104.056 at Dose C (optional)

The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.

Sponsors & Collaborators

  • ICON Clinical Research

    collaborator INDUSTRY

  • AC Immune SA

    lead INDUSTRY

Principal Investigators

  • Daniela Berg, Prof. · Klinik für Neurologie, UKSH Campus Kiel, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-24
Primary Completion
2028-01-31
Completion
2028-01-31

Countries

  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06015841 on ClinicalTrials.gov